Alpha-CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosis.
Tomaske
Maren
M
Intensive Care Unit, Children's Hospital of the University of Tübingen, Tübingen, Germany. Maren.Tomaske@med.uni-tuebingen.de
Amon
Oliver
O
Bosk
Axel
A
Handgretinger
Rupert
R
Schneider
E Marion
EM
Niethammer
Dietrich
D
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects; D002648:Child; D000077561:Daclizumab; D005047:Etoposide / Q000009:adverse effects; D015616:Histiocytosis, Non-Langerhans-Cell / Q000188:drug therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007970:Leukopenia / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D005047:Etoposide; D000077561:Daclizumab